obsolete_cleft palate: ['Congenital fissure of the soft and/or hard palate, due to faulty fusion.']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditions
|
519067 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
403 |
4. Check minimum number of eventsNone |
403 |
5. Include endpointsNone |
403 |
6. Filter based on genotype QC (FinnGen only) |
389 |
Control definitions (FinnGen only)
- Control exclude
- Q17_CLEFT_LIP_CLEFT_PALATE
Extra metadata
- First used in FinnGen datafreeze
- DF7
Similar endpoints
↥List of similar endpoints to
Cleft palate
based on the number of shared cases.
Similar with more cases:
- Cleft lip, lip and palate or palate
- Congenital malformations, deformations and chromosomal abnormalities
- Congenital malformations, deformations and chromosomal abnormalities, including avohilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5369 | 3001 | 2360 |
| Only index persons | 4471 | 2522 | 1949 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.09 | 0.07 |
| Only index persons | 0.08 | 0.09 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 1.83 | 1.71 | 1.86 |
| Only index persons | 1.89 | 1.81 | 1.99 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 389 | 268 | 121 |
| Unadjusted period prevalence (%) | 0.08 | 0.10 | 0.06 |
| Median age at first event (years) | 2.70 | 2.05 | 4.15 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 402
- Matched controls
- 4020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q35.1
ICD-10 Finland
Cleft hard palate
3351.5
205.7
181
*
74900
ICD-8 Finland
Cleft palate and cleft lip, Cleft palate
+∞
193.9
170
*
4122
FHL
Tympanostomy (tympanic tube)
20.6
118.7
98
62
7490A
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate[PALATOSCHISIS COMPLETA]
+∞
90.1
83
*
4364
FHL
Pharyngeal tongue plastic
+∞
77.7
72
*
3812A
ICD-9 Finland
Nonsuppurative otitis media and Eustachian tube disorders, Chronic mucoid otitis media
15.5
76.2
71
55
4362
FHL
Nozzle reconstruction
+∞
65.4
61
*
Q35.71
ICD-10 Finland
Submucous cleft palate
618.8
56.0
54
*
Q35.9
ICD-10 Finland
Cleft palate, unspecified
592.3
53.8
52
*
Q37.1
ICD-10 Finland
Cleft hard palate with unilateral cleft lip
+∞
53.3
50
*
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
9.1
52.7
71
93
H72.0
ICD-10 Finland
Central perforation of tympanic membrane
16.9
51.0
44
29
EB1MA
NOMESCO Finland
Cephalometry with X-ray
9.7
50.7
64
77
SJX10
NOMESCO Finland
Orthodontic treatment/control appointment, short
7.8
48.1
74
113
SAA04
NOMESCO Finland
Special examination of mouth
7.4
46.8
76
123
7490C
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate[PALATOSCHISIS SUBMUCOSAE]
+∞
43.5
41
*
7490B
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate[PALATOSCHISIS INCOMPLETA]
+∞
42.5
40
*
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
7.7
41.2
63
95
H65.3
ICD-10 Finland
Chronic mucoid otitis media
8.5
40.9
57
77
SBB10
NOMESCO Finland
Dental impressions
4.8
36.1
99
258
4451
FHL
Guitar cutting
6.0
34.7
68
132
K00.00
ICD-10 Finland
Hypodontia
12.3
31.3
32
28
74920
ICD-8 Finland
Cleft palate and cleft lip, Cheilognathopalatoschisis unilateralis
+∞
26.3
25
*
7492A
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate with cleft lip[CHEILOPALATOSCHISIS UNILATERALIS COMPLETA]
+∞
26.3
25
*
Q35.3
ICD-10 Finland
Cleft soft palate
277.5
26.0
26
*
SJD00
NOMESCO Finland
Removal and/or reactivation of orthodontic arch wire
5.9
25.6
49
92
4361
FHL
Lip plastic or reconstruction due to cleft lip
+∞
25.3
24
*
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
6.1
24.7
46
84
SJB00
NOMESCO Finland
Fitting of removable appliance incl. patient instructions
6.0
23.4
44
81
UDC00
NOMESCO Finland
Ear microscopy
4.8
23.4
58
137
SJC50
NOMESCO Finland
Removal of fixed orthodontic appliance with at least 7 brackets
6.2
23.4
42
74
Q37.0
ICD-10 Finland
Cleft hard palate with bilateral cleft lip
+∞
23.1
22
*
4368
FHL
Closing the fistula of the mouth
+∞
22.1
21
*
1450
FHL
Otomicroscopy
23.9
20.7
29
13
K07.25
ICD-10 Finland
Anomalies of dental arch relationship
6.2
20.6
37
65
38401
ICD-8 Finland
Other inflammatory diseases of ear, Rhinosalpingitis (otosalpingitis) chronica adhaesiva
20.1
20.3
30
16
EAB30
NOMESCO Finland
Correction of cleft lip
+∞
20.0
19
*
EBB10
NOMESCO Finland
Insertion of dental implant
17.9
19.5
30
18
EHC40
NOMESCO Finland
Repair of submucous cleft palate
198.9
18.7
19
*
SJD20
NOMESCO Finland
Placement of modified orthodontic arch wire
5.9
17.7
33
60
EHC10
NOMESCO Finland
Plastic repair of oronasal or oroantral fistula of palate
187.9
17.7
18
*
38402
ICD-8 Finland
Other inflammatory diseases of ear, Rhinosalpingitis (otosalpingitis) non definita
14.8
17.6
29
21
EEC05
NOMESCO Finland
Le Fort I osteotomy
66.3
16.9
19
*
ECB17
NOMESCO Finland
Operation of gingival cleft
+∞
16.8
16
*
SPA00
NOMESCO Finland
Changing form of teeth in prepation for prosthodontic work
7.3
16.7
25
36
SJD30
NOMESCO Finland
Demanding placement of orthodontic arch wire
6.9
16.4
26
40
ENC80
NOMESCO Finland
Plastic operation of soft palate for voice distubance
+∞
15.7
15
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
3.0
14.7
74
281
4121
FHL
Tympanic puncture or parasentosis in general anesthesia or operating room
11.0
14.5
27
26
EBB15
NOMESCO Finland
Insertion of dental implant abutment
28.4
14.4
19
7
QA4S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in face
23.3
14.4
20
9
H66.0
ICD-10 Finland
Acute suppurative otitis media
2.8
14.0
85
357
74929
ICD-8 Finland
Cleft palate and cleft lip, Unspecified
+∞
13.6
13
*
SJA01
NOMESCO Finland
Assesment of orthodontic treatment need
41.6
13.2
16
*
SJB60
NOMESCO Finland
Adjustment and grinding of removable appliance
5.2
12.8
27
55
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
3.4
12.7
48
153
4367
FHL
Bone transfer to the upper jaw
+∞
12.6
12
*
4365
FHL
Correction of nasal deformity
+∞
12.6
12
*
H66.9
ICD-10 Finland
Otitis media, unspecified
2.8
12.5
71
287
SJD40
NOMESCO Finland
Placement of prefabricated palatal or lingual arch
4.2
12.5
34
86
ECB40
NOMESCO Finland
Surgical treatment of fracture of alveolus
27.7
12.1
16
6
DCD00
NOMESCO Finland
Myringoplasty
19.7
11.7
17
9
ZSZ10
NOMESCO Finland
Secondary repair operation
67.0
11.7
13
*
Q35.70
ICD-10 Finland
Cleft uvula
+∞
11.5
11
*
74924
ICD-8 Finland
Cleft palate and cleft lip, Cheilognathopalatoschisis bilateralis
+∞
11.5
11
*
7492C
ICD-9 Finland
Cleft palate and cleft lip, Cleft palate with cleft lip[CHEILOPALATOSCHISIS BILATERALIS COMPLETA]
+∞
11.5
11
*
ZXB10
NOMESCO Finland
Medial
17.7
11.3
17
10
38110
ICD-8 Finland
Otitis media without mention of mastoiditis, Chronic
28.9
10.8
14
5
4141
FHL
Myringoplasty (also for reasons other than inflammation)
61.7
10.7
12
*
3842A
ICD-9 Finland
Other disorders of tympanic membrane, Perforation of tympanic membrane
61.7
10.7
12
*
H65.9
ICD-10 Finland
Nonsuppurative otitis media, unspecified
10.5
10.6
20
20
SJD10
NOMESCO Finland
Placement of orthodontic arch wire
3.9
10.5
32
88
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
3.2
10.4
44
150
ZZH21
NOMESCO Finland
Graft of patients own bone, small pieces
11.0
10.4
19
18
SPC20
NOMESCO Finland
Implant borne crown
19.4
10.3
15
8
H74.1
ICD-10 Finland
Adhesive middle ear disease
41.2
10.0
12
*
H72.2
ICD-10 Finland
Other marginal perforations of tympanic membrane
17.2
9.9
15
9
ZXD10
NOMESCO Finland
Scheduled procedure
2.0
9.8
147
893
H90.6
ICD-10 Finland
Mixed conductive and sensorineural hearing loss, bilateral
15.5
9.6
15
10
Q35
ICD-10 Finland
Cleft palate
102.3
9.5
10
*
SJA03
NOMESCO Finland
Demanding workplan for orthodontic treatment
30.8
9.5
12
*
Q36.9
ICD-10 Finland
Cleft lip, unilateral
+∞
9.4
9
*
EHC30
NOMESCO Finland
Reconstruction of palate
+∞
9.4
9
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
3.6
9.2
31
91
78159
ICD-8 Finland
Other symptoms referable to nervous system and special senses, Laesio loquendi alia sive NUD
37.6
9.1
11
*
ZXA10
NOMESCO Finland
Bilateral
2.4
9.0
71
334
WZC00
NOMESCO Finland
Treatment plan or consultation
1.9
8.9
166
1079
DFF00
NOMESCO Finland
Pure tone audiometry
3.0
8.8
40
142
SAA03
NOMESCO Finland
Extended examination of mouth
1.9
8.7
207
1454
R1260
NOMESCO Finland
Evaluation of communicative skills
10.4
8.6
16
16
SPF10
NOMESCO Finland
Demanding reparation of dental prosthesis
28.2
8.5
11
*
EBB11
NOMESCO Finland
Insertion of additional dental implant in one session
20.6
8.5
12
6
K07.14
ICD-10 Finland
Retrognaty, maxillary
20.6
8.5
12
6
38100
ICD-8 Finland
Otitis media without mention of mastoiditis, Acute
4.1
8.5
23
58
3820A
ICD-9 Finland
Suppurative and unspecified otitis media, Acute suppurative otitis media
4.8
8.4
19
41
DLW00
NOMESCO Finland
Correction of cleft nose
+∞
8.4
8
*
Q35.7
ICD-10 Finland
Cleft uvula
+∞
8.4
8
*
SJC01
NOMESCO Finland
Positioning and fixed attachment of single bracket (Bracket with fixed attachment)
3.9
8.3
25
68
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.8
8.3
194
1349
XX9AW
NOMESCO Finland
Production of copy from X-ray picture
3.8
8.1
25
69
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
6.5
8.1
20
32
J01DA08
ATC
[U] cefaclor
2.2
8.1
82
428
H04
ICPC
Ear discharge
4.6
8.0
19
43
H65.2
ICD-10 Finland
Chronic serous otitis media
7.2
7.9
18
26
S02CA02
ATC
flumetasone and antiinfectives; otic
3.6
7.8
26
76
H90.0
ICD-10 Finland
Conductive hearing loss, bilateral
18.8
7.6
11
6
SPF20
NOMESCO Finland
Temporary relining of dentures
25.6
7.6
10
*
SJA04
NOMESCO Finland
Very demanding workplan for orthodontic treatment
25.6
7.6
10
*
Z2221
NOMESCO Finland
Medical doctor
1.9
7.5
126
784
R49.2
ICD-10 Finland
Hypernasality and hyponasality
81.5
7.4
8
*
4347
FHL
Osteotomy of the upper jaw
81.5
7.4
8
*
9808
FHL
Bone graft
81.5
7.4
8
*
Q37.99
ICD-10 Finland
Cleft palate with cleft lip NOS
+∞
7.3
7
*
74912
ICD-8 Finland
Cleft palate and cleft lip, Cheilognathoschisis unilateralis
+∞
7.3
7
*
K01.0
ICD-10 Finland
Embedded teeth
4.1
7.2
20
51
H65.0
ICD-10 Finland
Acute serous otitis media
4.6
7.2
17
38
SJX21
NOMESCO Finland
Therapeutic intervention or check-up related to orthodontic treatment
3.6
6.8
22
63
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
12.5
6.6
11
9
WZC05
NOMESCO Finland
Specialty-specific consultation based on referral by dentist or doctor
2.8
6.6
33
124
K07.30
ICD-10 Finland
Spacing, abnormal of tooth or teeth
3.1
6.6
28
96
ZZG00
NOMESCO Finland
Graft of cartilage
70.9
6.4
7
*
4741B
ICD-9 Finland
Chronic disease of tonsils and adenoids, Hypertrophy of tonsils and adenoids[HYPERTROPHIA TONSILLAE PHARYNGICAE]
3.8
6.3
19
52
Q37.90
ICD-10 Finland
Unspecified cheft palate with cleft lip, unilateral
+∞
6.3
6
*
EH1JB
NOMESCO Finland
Functional examination of palate
+∞
6.3
6
*
Q37.3
ICD-10 Finland
Cleft soft palate with unilateral cleft lip
+∞
6.3
6
*
4363
FHL
Hidden slit reconstruction
+∞
6.3
6
*
H72.1
ICD-10 Finland
Attic perforation of tympanic membrane
+∞
6.3
6
*
SPA20
NOMESCO Finland
Selection and insertion of implant abutment
27.1
6.2
8
*
SJC40
NOMESCO Finland
Removal of fixed orthodontic appliance with at most 6 brackets
3.0
6.2
27
94
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
1.7
6.2
144
980
SJC02
NOMESCO Finland
Positioning and fixed attachment of brackets
3.9
6.2
18
48
SJD50
NOMESCO Finland
Placement of prefabricated palatal or lingual arch, dentist-made
8.8
6.1
12
14
SJC03
NOMESCO Finland
Positioning and fixed attachment of brackets, extensive
3.6
6.1
20
58
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
2.4e+00
3.3e+00
—
1.0e+50
—
3.6e+00
2.7e+00
cases:10.53%
controls:1.09%
cases:13.16%
controls:0.54%
—
—
cases:14.04%
controls:0.00%
—
—
cases:16.81%
controls:0.55%
cases:18.75%
controls:1.48%
12
12
102
1089
15
6
99
1095
—
16
0
98
1101
—
19
6
94
1091
21
16
91
1065
Outpatient Visit
OP [9202]
OP [9202]
3.7e-01
8.4e-01
6.5e-01
5.7e+00
1.6e+00
1.4e+00
6.3e-01
cases:59.65%
controls:50.41%
cases:54.39%
controls:34.06%
cases:16.67%
controls:9.45%
cases:61.40%
controls:0.54%
cases:30.70%
controls:8.17%
cases:69.03%
controls:35.37%
cases:72.32%
controls:58.28%
68
555
46
546
62
375
52
726
19
104
95
997
70
6
44
1095
35
90
79
1011
78
388
35
709
81
630
31
451
Dental impressions
SBB10 [2001310299]
SBB10 [2001310299]
2.7e+00
—
—
—
—
2.0e+00
2.1e+00
cases:6.14%
controls:0.45%
—
—
—
—
—
—
—
—
cases:5.31%
controls:0.73%
cases:15.18%
controls:2.04%
7
5
107
1096
—
—
—
—
6
8
107
1089
17
22
95
1059
Dentistry
C5 [903277]
C5 [903277]
9.6e-01
2.1e+00
—
1.0e+50
—
2.7e+00
2.0e+00
cases:8.77%
controls:3.54%
cases:11.40%
controls:1.54%
—
—
cases:24.56%
controls:0.00%
—
—
cases:18.58%
controls:1.55%
cases:19.64%
controls:3.24%
10
39
104
1062
13
17
101
1084
—
28
0
86
1101
—
21
17
92
1080
22
35
90
1046
Otolaryngology
4 [38004449]
4 [38004449]
9.7e-01
2.0e+00
—
—
—
1.7e+00
1.1e+00
cases:21.05%
controls:9.17%
cases:18.42%
controls:3.09%
—
—
—
—
—
—
cases:15.93%
controls:3.37%
cases:22.32%
controls:8.42%
24
101
90
1000
21
34
93
1067
—
—
—
18
37
95
1060
25
91
87
990
General Surgery
2 [38004447]
2 [38004447]
-2.7e-02
5.0e-01
-1.0e+50
1.0e+50
2.6e+00
1.9e+00
8.0e-01
cases:14.91%
controls:15.26%
cases:7.02%
controls:4.36%
cases:0.00%
controls:0.64%
cases:13.16%
controls:0.00%
cases:9.65%
controls:0.82%
cases:18.58%
controls:3.46%
cases:27.68%
controls:14.62%
17
168
97
933
8
48
106
1053
0
7
114
1094
15
0
99
1101
11
9
103
1092
21
38
92
1059
31
158
81
923
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
K08.1 [45591573]
—
1.0e+50
—
—
—
—
3.1e+00
—
—
cases:4.39%
controls:0.00%
—
—
—
—
—
—
—
—
cases:9.82%
controls:0.46%
—
5
0
109
1101
—
—
—
—
11
5
101
1076
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
1.5e+00
—
—
1.0e+50
—
2.9e+00
—
cases:4.39%
controls:1.00%
—
—
—
—
cases:5.26%
controls:0.00%
—
—
cases:7.96%
controls:0.46%
—
—
5
11
109
1090
—
—
6
0
108
1101
—
9
5
104
1092
—
Audiology
64 [38004489]
64 [38004489]
9.6e-01
—
—
1.0e+50
—
2.7e+00
1.5e+00
cases:4.39%
controls:1.73%
—
—
—
—
cases:4.39%
controls:0.00%
—
—
cases:6.19%
controls:0.46%
cases:7.14%
controls:1.67%
5
19
109
1082
—
—
5
0
109
1101
—
7
5
106
1092
8
18
104
1063
Outpatient Hospital
22 [8756]
22 [8756]
2.1e-01
1.1e+00
-1.0e+50
1.0e+50
—
1.5e+00
6.9e-01
cases:24.56%
controls:20.89%
cases:14.91%
controls:5.72%
cases:0.00%
controls:0.54%
cases:10.53%
controls:0.00%
—
—
cases:20.35%
controls:5.29%
cases:33.04%
controls:19.89%
28
230
86
871
17
63
97
1038
0
6
114
1095
12
0
102
1101
—
23
58
90
1039
37
215
75
866
Nonsuppurative otitis media and Eustachian tube disorders, Chronic mucoid otitis media
3812A [2000403465]
3812A [2000403465]
2.5e+00
—
—
—
—
—
—
cases:5.26%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
108
1096
—
—
—
—
—
—
Operative extraction of tooth
EBA10 [2001301925]
EBA10 [2001301925]
2.5e+00
—
—
—
—
—
—
cases:5.26%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
108
1096
—
—
—
—
—
—
Removal and/or reactivation of orthodontic arch wire
SJD00 [2001310437]
SJD00 [2001310437]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.36%
controls:0.65%
—
—
—
—
—
—
6
7
106
1074
Orthodontic treatment/control appointment, short
SJX10 [2001310452]
SJX10 [2001310452]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.14%
controls:0.93%
—
—
—
—
—
—
8
10
104
1071
Clinical photography of mouth and teeth
SBB00 [2001310298]
SBB00 [2001310298]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.82%
controls:1.39%
—
—
—
—
—
—
11
15
101
1066
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
5.8e-01
—
—
—
—
2.0e+00
7.7e-01
cases:6.14%
controls:3.54%
—
—
—
—
—
—
—
—
cases:5.31%
controls:0.73%
cases:8.93%
controls:4.35%
7
39
107
1062
—
—
—
—
6
8
107
1089
10
47
102
1034
Inpatient Hospital
21 [8717]
21 [8717]
7.8e-02
6.2e-01
—
1.0e+50
1.5e+00
1.1e+00
3.8e-01
cases:30.70%
controls:29.06%
cases:15.79%
controls:9.17%
—
—
cases:10.53%
controls:0.00%
cases:4.39%
controls:1.00%
cases:22.12%
controls:8.57%
cases:34.82%
controls:26.73%
35
320
79
781
18
101
96
1000
—
12
0
102
1101
5
11
109
1090
25
94
88
1003
39
289
73
792
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
2.5e-01
3.3e-01
—
—
—
5.4e-01
7.6e-01
cases:23.68%
controls:19.53%
cases:8.77%
controls:6.45%
—
—
—
—
—
—
cases:13.27%
controls:8.20%
cases:45.54%
controls:28.12%
27
215
87
886
10
71
104
1030
—
—
—
15
90
98
1007
51
304
61
777
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
—
-1.0e+50
—
—
—
-1.0e+50
5.9e-01
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:1.09%
cases:5.36%
controls:3.05%
—
0
9
114
1092
—
—
—
0
12
113
1085
6
33
106
1048
Dental calculus supragingival
K03.64 [2000502689]
K03.64 [2000502689]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
114
1087
—
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
0
10
113
1087
—
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.54%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
6
114
1095
0
5
114
1096
—
—
—
0
5
113
1092
—
Cleft hard palate with unilateral cleft lip
Q37.1 [45582645]
Q37.1 [45582645]
1.0e+50
1.0e+50
1.0e+50
—
—
1.0e+50
1.0e+50
cases:9.65%
controls:0.00%
cases:11.40%
controls:0.00%
cases:4.39%
controls:0.00%
—
—
—
—
cases:9.73%
controls:0.00%
cases:11.61%
controls:0.00%
11
0
103
1101
13
0
101
1101
5
0
109
1101
—
—
11
0
102
1097
13
0
99
1081
itraconazole; oral, parenteral
J02AC02 [21603081]
J02AC02 [21603081]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
114
1089
—
—
—
—
—
—
Stomach Pathology biopsy report
66114-0 [40768797]
66114-0 [40768797]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
114
1092
—
—
—
—
—
—
tizanidine; oral
M03BX02 [21604116]
M03BX02 [21604116]
-5.7e-01
—
—
—
—
7.7e-01
1.3e-01
cases:4.39%
controls:7.54%
—
—
—
—
—
—
—
—
cases:4.42%
controls:2.10%
cases:11.61%
controls:10.36%
5
83
109
1018
—
—
—
—
5
23
108
1074
13
112
99
969
hydrocortisone butyrate
D07AB02 [21602106]
D07AB02 [21602106]
—
—
-1.0e+50
—
—
—
4.4e-01
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:9.82%
controls:6.57%
—
—
0
6
114
1095
—
—
—
11
71
101
1010
Inhalation anesthesia
WX400 [2001310805]
WX400 [2001310805]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
114
1093
—
—
—
—
—
—
valsartan; oral
C09CA03 [21601826]
C09CA03 [21601826]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.65%
—
—
—
—
—
0
5
113
1092
0
7
112
1074
Other disturbance in the tooth eruption
K00.68 [2000502648]
K00.68 [2000502648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
tolterodine; oral
G04BD07 [21602640]
G04BD07 [21602640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Musculoskeletal sympt/complt other
L29 [2002000648]
L29 [2002000648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Shoulder lesions
M75 [45557983]
M75 [45557983]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
114
1089
—
—
—
—
—
—
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
0
7
114
1094
—
—
—
—
0
6
113
1091
—
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
14927-8 [3025839]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
0
5
114
1096
0
7
114
1094
—
—
—
0
11
113
1086
—
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
9
114
1092
0
5
114
1096
—
—
—
—
—
Respiratory infection other
R83 [2002000951]
R83 [2002000951]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:1.48%
0
9
114
1092
0
9
114
1092
—
—
—
0
9
113
1088
0
16
112
1065
Fissure sealant
SCE00 [2001310316]
SCE00 [2001310316]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
4.7e-01
—
—
—
—
—
5.2e-01
cases:5.26%
controls:3.36%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:3.79%
6
37
108
1064
—
—
—
—
—
7
41
105
1040
Proliferative diabetic retinopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.03*E10.3 [2000503982]
H36.03*E10.3 [2000503982]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
3.2e-01
4.2e-01
—
—
—
7.2e-01
4.3e-01
cases:26.32%
controls:20.62%
cases:12.28%
controls:8.45%
—
—
—
—
—
—
cases:15.04%
controls:7.93%
cases:34.82%
controls:25.72%
30
227
84
874
14
93
100
1008
—
—
—
17
87
96
1010
39
278
73
803
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
4498-2 [3017766]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Cephalometry with X-ray
EB1MA [2001301916]
EB1MA [2001301916]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.46%
controls:1.57%
—
—
—
—
—
—
5
17
107
1064
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
6
113
1091
—
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
WX602 [2001310813]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
-1.3e-01
-3.7e-02
—
—
—
-1.0e-01
-2.5e-01
cases:7.02%
controls:7.90%
cases:5.26%
controls:5.45%
—
—
—
—
—
—
cases:5.31%
controls:5.83%
cases:10.71%
controls:13.32%
8
87
106
1014
6
60
108
1041
—
—
—
6
64
107
1033
12
144
100
937
drospirenone and ethinylestradiol
G03AA12 [21602485]
G03AA12 [21602485]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
10
112
1071
Menstrual pain
X02 [2002001287]
X02 [2002001287]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Laparoscopic cholecystectomy
JKA21 [2001305294]
JKA21 [2001305294]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
—
—
-1.0e+50
—
—
—
2.2e-01
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:8.93%
controls:7.31%
—
—
0
6
114
1095
—
—
—
10
79
102
1002
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
—
—
—
1.0e+50
—
—
1.1e+00
—
—
—
—
—
—
cases:4.39%
controls:0.00%
—
—
—
—
cases:6.25%
controls:2.13%
—
—
—
5
0
109
1101
—
—
7
23
105
1058
duloxetine; oral
N06AX21 [21604749]
N06AX21 [21604749]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
114
1092
—
—
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
112
1073
hydrocortisone
A07EA02 [21600654]
A07EA02 [21600654]
—
—
-1.0e+50
—
—
—
3.9e-01
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:9.82%
controls:6.85%
—
—
0
6
114
1095
—
—
—
11
74
101
1007
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
-2.2e-01
2.2e-01
—
—
-1.0e+50
—
-1.2e-01
cases:7.02%
controls:8.63%
cases:5.26%
controls:4.27%
—
—
—
—
cases:0.00%
controls:1.00%
—
—
cases:13.39%
controls:14.89%
8
95
106
1006
6
47
108
1054
—
—
0
11
114
1090
—
15
161
97
920
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
M51.1 [45562747]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
113
1092
—
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
K21.0 [45543296]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
7
114
1094
—
—
—
—
—
0
6
112
1075
glucagon; nasal, parenteral
H04AA01 [21602778]
H04AA01 [21602778]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:5.64%
—
0
16
114
1085
—
—
—
—
0
61
112
1020
Counselling related to known health issue
SPAT1310 [2001700411]
SPAT1310 [2001700411]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
—
—
0
14
114
1087
—
—
—
—
0
12
113
1085
—
Placement of prefabricated palatal or lingual arch
SJD40 [2001310441]
SJD40 [2001310441]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.46%
controls:1.11%
—
—
—
—
—
—
5
12
107
1069
Colonoscopy Study observation
28023-0 [3022145]
28023-0 [3022145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
114
1092
—
—
—
—
—
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
—
—
—
—
-1.0e+50
—
-2.8e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
cases:4.46%
controls:5.83%
—
—
—
—
0
6
114
1095
—
5
63
107
1018
Migraine with aura [classical migraine]
G43.1 [45562086]
G43.1 [45562086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Assessment of need for medical rehabilitation
SPAT1215 [2001700316]
SPAT1215 [2001700316]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
112
1073
Actinic keratosis
L57.0 [45591640]
L57.0 [45591640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
112
1073
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
72171-2 [43054914]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
Extraction of tooth
EBA00 [2001301923]
EBA00 [2001301923]
—
-1.0e+50
—
—
—
—
4.1e-01
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:8.93%
controls:6.11%
—
0
7
114
1094
—
—
—
—
10
66
102
1015
Chronic tonsillitis
J35.0 [45548113]
J35.0 [45548113]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
5
114
1096
—
—
—
—
—
0
6
112
1075
Exploration of soft tissue of pelvis, percutaneous
NEA10 [2001307877]
NEA10 [2001307877]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
114
1092
—
—
—
—
—
—
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
D01AC20 [21601936]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:1.09%
—
—
—
0
13
114
1088
—
—
0
5
114
1096
0
12
113
1085
—
Besnier prurigo
L20.0 [45562534]
L20.0 [45562534]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
8
114
1093
0
6
114
1095
—
—
—
0
5
113
1092
—
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
LC2BE [2001306544]
—
-1.0e+50
—
—
—
-1.0e+50
4.9e-01
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:4.46%
controls:2.78%
—
0
9
114
1092
—
—
—
0
10
113
1087
5
30
107
1051
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
546-2 [3024135]
—
-1.0e+50
—
—
—
—
4.1e-01
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
cases:5.36%
controls:3.61%
—
0
11
114
1090
—
—
—
—
6
39
106
1042
Periodontal treatment, brief
SDA02 [2001310327]
SDA02 [2001310327]
—
-1.0e+50
—
—
—
—
7.2e-01
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:7.14%
controls:3.61%
—
0
5
114
1096
—
—
—
—
8
39
104
1042
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
SPAT1306 [2001700407]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
113
1092
—
Rash localized
S06 [2002000971]
S06 [2002000971]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
112
1073
telmisartan and diuretics
C09DA07 [21601839]
C09DA07 [21601839]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
dapagliflozin; oral
A10BK01 [1123890]
A10BK01 [1123890]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
113
1092
—
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
2500B [2000402295]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:6.09%
cases:0.00%
controls:1.45%
—
—
—
—
—
—
cases:0.00%
controls:1.82%
cases:0.00%
controls:2.50%
0
67
114
1034
0
16
114
1085
—
—
—
0
20
113
1077
0
27
112
1054
Cleft uvula
Q35.70 [2000503338]
Q35.70 [2000503338]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:4.39%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
109
1101
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
M01AE03 [21603969]
-7.8e-02
—
—
—
—
—
6.3e-01
cases:4.39%
controls:4.72%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:3.42%
5
52
109
1049
—
—
—
—
—
7
37
105
1044
eletriptan; oral
N02CC06 [21604381]
N02CC06 [21604381]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
0
5
114
1096
—
—
—
—
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
14771-0 [3018251]
-2.2e-02
—
—
—
—
4.1e-01
-1.7e-01
cases:6.14%
controls:6.27%
—
—
—
—
—
—
—
—
cases:6.19%
controls:4.19%
cases:11.61%
controls:13.41%
7
69
107
1032
—
—
—
—
7
46
106
1051
13
145
99
936
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
—
-1.0e+50
—
—
—
-1.0e+50
1.2e+00
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:5.36%
controls:1.76%
—
0
8
114
1093
—
—
—
0
5
113
1092
6
19
106
1062
Disturbance of activity and attention
F90.0 [45542870]
F90.0 [45542870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
J07AM51 [21601317]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
13
112
1068
Internal derangement of knee, unspecified
M23.9 [45567507]
M23.9 [45567507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
112
1073
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
E11.9 [45561952]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.54%
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
0
17
114
1084
0
12
114
1089
—
—
—
—
—
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
7.2e-01
—
—
—
—
—
9.1e-01
cases:4.39%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
cases:4.46%
controls:1.85%
5
24
109
1077
—
—
—
—
—
5
20
107
1061
amlodipine; oral
C08CA01 [21601747]
C08CA01 [21601747]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
0
8
114
1093
—
—
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
General and Unspecified, Clarification/discussion RFE/demand
A48 [2002000182]
A48 [2002000182]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Recording of ECG
SPAT1097 [2001700198]
SPAT1097 [2001700198]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
6
114
1095
—
—
—
—
—
0
5
112
1076
alprazolam; oral
N05BA12 [21604577]
N05BA12 [21604577]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
0
7
113
1090
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
—
1.5e+00
—
—
—
—
2.0e-01
—
—
cases:4.39%
controls:1.00%
—
—
—
—
—
—
—
—
cases:8.04%
controls:6.66%
—
5
11
109
1090
—
—
—
—
9
72
103
1009
Benign paroxysmal vertigo
H81.1 [45572061]
H81.1 [45572061]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
16933-4 [3021879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
9
112
1072
roxithromycin; oral
J01FA06 [21602974]
J01FA06 [21602974]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:5.55%
—
—
—
—
—
—
7
60
105
1021
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
0
11
114
1090
—
—
—
0
16
113
1081
—
other preparations, combinations; ointment
C05AX03 [21601631]
C05AX03 [21601631]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
0
5
114
1096
—
—
—
0
6
113
1091
—
Polysomnography panel
90568-7 [1002224]
90568-7 [1002224]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
Postpartum check-up
SPAT1380 [2001700480]
SPAT1380 [2001700480]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
chloramphenicol
S02AA01 [21605147]
S02AA01 [21605147]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
10
112
1071
phenylephrine, combinations
R01BA53 [21603214]
R01BA53 [21603214]
7.9e-01
—
—
—
—
-1.0e+50
—
cases:5.26%
controls:2.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
6
27
108
1074
—
—
—
—
0
6
113
1091
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
-1.1e-01
-1.3e-02
—
—
—
-2.2e-02
-1.2e-01
cases:9.65%
controls:10.63%
cases:7.89%
controls:7.99%
—
—
—
—
—
—
cases:8.85%
controls:9.02%
cases:18.75%
controls:20.63%
11
117
103
984
9
88
105
1013
—
—
—
10
99
103
998
21
223
91
858
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
114
1083
—
—
—
—
—
—
General Practice
1 [38004446]
1 [38004446]
2.7e-01
—
—
—
—
—
1.4e-01
cases:7.02%
controls:5.45%
—
—
—
—
—
—
—
—
—
—
cases:7.14%
controls:6.29%
8
60
106
1041
—
—
—
—
—
8
68
104
1013
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
SPAT1230 [2001700331]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:1.02%
—
—
—
—
—
0
6
113
1091
0
11
112
1070
terbinafine; oral
D01BA02 [21601967]
D01BA02 [21601967]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
0
7
114
1094
—
—
—
0
9
113
1088
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
0
6
114
1095
—
—
—
—
0
14
112
1067
insulin lispro; parenteral
A10AC04 [21600726]
A10AC04 [21600726]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
6
114
1095
—
0
8
114
1093
—
—
Demanding periodontal treatment
SDA04 [2001310329]
SDA04 [2001310329]
—
—
—
—
—
-1.0e+50
9.1e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:4.46%
controls:1.85%
—
—
—
—
—
0
7
113
1090
5
20
107
1061
hydrocortisone aceponate
D07AC16 [21602135]
D07AC16 [21602135]
—
—
-1.0e+50
—
—
—
4.4e-01
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:9.82%
controls:6.57%
—
—
0
6
114
1095
—
—
—
11
71
101
1010
isosorbide mononitrate; oral
C01DA14 [21600324]
C01DA14 [21600324]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
0
10
114
1091
0
7
114
1094
—
—
—
0
8
113
1089
—
Localized swelling, mass and lump, unspecified
R22.9 [45577788]
R22.9 [45577788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
carvedilol; oral
C07AG02 [21601700]
C07AG02 [21601700]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
10
114
1091
0
5
114
1096
—
—
—
—
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
1.6e-01
-7.8e-02
—
—
-1.0e+50
6.2e-01
-9.7e-03
cases:12.28%
controls:10.63%
cases:4.39%
controls:4.72%
—
—
—
—
cases:0.00%
controls:0.73%
cases:9.73%
controls:5.47%
cases:19.64%
controls:19.80%
14
117
100
984
5
52
109
1049
—
—
0
8
114
1093
11
60
102
1037
22
214
90
867
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
—
—
—
—
—
-1.0e+50
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:5.36%
controls:1.94%
—
—
—
—
—
0
6
113
1091
6
21
106
1060
carbimazole; oral
H03BB01 [21602765]
H03BB01 [21602765]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
loperamide oxide; oral
A07DA05 [21600648]
A07DA05 [21600648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
betamethasone
S02BA07 [21605169]
S02BA07 [21605169]
3.4e-01
—
—
—
—
—
-8.9e-02
cases:5.26%
controls:3.81%
—
—
—
—
—
—
—
—
—
—
cases:5.36%
controls:5.83%
6
42
108
1059
—
—
—
—
—
6
63
106
1018
hydrocortisone and antiinfectives
S02CA03 [21605175]
S02CA03 [21605175]
—
-1.0e+50
—
—
—
—
1.2e+00
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:5.36%
controls:1.76%
—
0
5
114
1096
—
—
—
—
6
19
106
1062
chondroitin sulfate
M01AX25 [21604013]
M01AX25 [21604013]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
5
114
1096
—
—
—
0
5
113
1092
—
Dysphagia
R13 [45573013]
R13 [45573013]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
114
1096
—
—
—
—
—
0
5
112
1076
Feeling depressed
P03 [2002000800]
P03 [2002000800]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
0
5
114
1096
—
—
—
—
—
0
11
112
1070
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
31017-7 [3019050]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
3255-7 [3016407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
Nutritional therapy
R4190 [2001310243]
R4190 [2001310243]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
pramipexole; oral
N04BC05 [21604477]
N04BC05 [21604477]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
L17 [2002000641]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
113
1092
—
No procedures
SPAT1301 [2001700402]
SPAT1301 [2001700402]
—
-1.0e+50
—
—
—
—
2.5e-01
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:4.46%
controls:3.52%
—
0
7
114
1094
—
—
—
—
5
38
107
1043
dexchlorpheniramine, combinations
R06AB52 [21603467]
R06AB52 [21603467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
0
12
112
1069
Diabetes non-insulin dependent
T90 [2002001131]
T90 [2002001131]
-1.0e+50
-1.0e+50
—
—
—
—
6.8e-01
cases:0.00%
controls:0.73%
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
cases:4.46%
controls:2.31%
0
8
114
1093
0
11
114
1090
—
—
—
—
5
25
107
1056
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
MA2HE [2001306836]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
113
1092
—
Pain, unspecified
R52.9 [45544151]
R52.9 [45544151]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
potassium chloride; oral
A12BA01 [21600877]
A12BA01 [21600877]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
112
1073
Tear of meniscus, current
S83.2 [45555441]
S83.2 [45555441]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
TPH15 [2001309600]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
Thyrotoxicosis, unspecified
E05.9 [45586131]
E05.9 [45586131]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
Psoriasis vulgaris
L40.0 [45543370]
L40.0 [45543370]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
10
112
1071
Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]
WYA50 [2001310877]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Anoscopy
UJH02 [2001305182]
UJH02 [2001305182]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
chlorhexidine
S03AA04 [21605193]
S03AA04 [21605193]
—
—
—
—
—
-1.0e+50
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:4.46%
controls:1.67%
—
—
—
—
—
0
6
113
1091
5
18
107
1063
hydrocortisone and antiseptics
D07BA04 [21602146]
D07BA04 [21602146]
—
—
—
—
—
-1.0e+50
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:4.46%
controls:1.67%
—
—
—
—
—
0
6
113
1091
5
18
107
1063
Cocaine [Presence] in Urine
3397-7 [3016879]
3397-7 [3016879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
3.4e-01
—
—
—
—
—
-8.9e-02
cases:5.26%
controls:3.81%
—
—
—
—
—
—
—
—
—
—
cases:5.36%
controls:5.83%
6
42
108
1059
—
—
—
—
—
6
63
106
1018
formoterol and beclometasone
R03AK08 [43534839]
R03AK08 [43534839]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
doxycycline; oral, parenteral
J01AA02 [21602800]
J01AA02 [21602800]
-1.8e-01
4.3e-01
—
—
—
8.8e-01
7.3e-02
cases:12.28%
controls:14.35%
cases:6.14%
controls:4.09%
—
—
—
—
—
—
cases:7.96%
controls:3.46%
cases:14.29%
controls:13.41%
14
158
100
943
7
45
107
1056
—
—
—
9
38
104
1059
16
145
96
936
Plugged feeling ear
H13 [2002000480]
H13 [2002000480]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
112
1073
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
-1.1e-01
-1.3e-02
—
—
—
-2.2e-02
-1.2e-01
cases:9.65%
controls:10.63%
cases:7.89%
controls:7.99%
—
—
—
—
—
—
cases:8.85%
controls:9.02%
cases:18.75%
controls:20.63%
11
117
103
984
9
88
105
1013
—
—
—
10
99
103
998
21
223
91
858
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
6
113
1091
—
Benign neoplasm: Skin of eyelid, including canthus
D23.1 [45600585]
D23.1 [45600585]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
Consultation of another employee
SPAT1260 [2001700361]
SPAT1260 [2001700361]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
0
6
114
1095
—
—
—
—
—
0
13
112
1068
Old myocardial infarction
I25.2 [45601025]
I25.2 [45601025]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.56%
—
—
—
—
—
0
5
113
1092
0
6
112
1075
Lateral epicondylitis
M77.1 [45572551]
M77.1 [45572551]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
5
114
1096
—
—
—
—
—
0
7
112
1074
Primary total prosthetic replacement of knee joint without patellar part
NGB20 [2001308094]
NGB20 [2001308094]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
hydrocortisone
C05AA01 [21601608]
C05AA01 [21601608]
—
—
-1.0e+50
—
—
—
3.9e-01
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:9.82%
controls:6.85%
—
—
0
6
114
1095
—
—
—
11
74
101
1007
insulin lispro; parenteral
A10AB04 [21600718]
A10AB04 [21600718]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
6
114
1095
—
0
8
114
1093
—
—
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
SPAT1028 [2001700129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
9
112
1072
Dermatitis due to ingested food
L27.2 [45596371]
L27.2 [45596371]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
10
114
1091
0
5
114
1096
—
—
—
—
—
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
70200-1 [42868674]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
0
6
114
1095
—
—
—
—
—
0
12
112
1069
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
chlorhexidine, combinations
D08AC52 [21602208]
D08AC52 [21602208]
—
—
—
—
—
-1.0e+50
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:4.46%
controls:1.67%
—
—
—
—
—
0
6
113
1091
5
18
107
1063
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1754-1 [3012516]
-1.0e+50
—
—
—
—
—
3.6e-01
cases:0.00%
controls:1.91%
—
—
—
—
—
—
—
—
—
—
cases:5.36%
controls:3.79%
0
21
114
1080
—
—
—
—
—
6
41
106
1040
betamethasone
S03BA03 [21605203]
S03BA03 [21605203]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
0
9
114
1092
—
—
—
0
9
113
1088
—
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
14928-6 [3026989]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
0
5
114
1096
0
5
114
1096
—
—
—
—
0
16
112
1065
Supervision of normal pregnancy, unspecified
Z34.9 [45566420]
Z34.9 [45566420]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
Coeliac disease
K90.0 [45586745]
K90.0 [45586745]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Cystoscopy
UKC02 [2001306005]
UKC02 [2001306005]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
0
9
114
1092
—
—
—
—
—
0
9
112
1072
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
-3.6e-02
1.4e+00
—
—
—
—
-1.7e-03
cases:4.39%
controls:4.54%
cases:5.26%
controls:1.36%
—
—
—
—
—
—
—
—
cases:8.04%
controls:8.05%
5
50
109
1051
6
15
108
1086
—
—
—
—
9
87
103
994
Asthma
R96 [2002000961]
R96 [2002000961]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
A10AC30 [21600727]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
cases:0.00%
controls:2.59%
—
0
14
114
1087
—
—
—
0
11
113
1086
0
28
112
1053
candesartan and diuretics
C09DA06 [21601838]
C09DA06 [21601838]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
PEF monitoring instruction
SPAT1058 [2001700159]
SPAT1058 [2001700159]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
0
6
114
1095
—
—
—
—
—
0
9
112
1072
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
1.4e+00
—
—
—
—
—
—
cases:7.89%
controls:2.09%
—
—
—
—
—
—
—
—
—
—
—
—
9
23
105
1078
—
—
—
—
—
—
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
14646-4 [3023602]
—
—
—
—
—
—
-3.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.71%
controls:14.34%
—
—
—
—
—
—
12
155
100
926
lymecycline; oral, parenteral
J01AA04 [21602802]
J01AA04 [21602802]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
0
8
114
1093
0
7
114
1094
—
—
—
—
—
Opiates [Presence] in Urine
3879-4 [3027008]
3879-4 [3027008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
Venous insufficiency (chronic)(peripheral)
I87.2 [45552867]
I87.2 [45552867]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
6
114
1095
—
—
—
—
—
0
7
112
1074
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
O04.9 [45543909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
0
12
112
1069
Midwife
Z3232 [2001311563]
Z3232 [2001311563]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
114
1093
—
—
—
—
—
—
lactulose; oral
A06AD11 [21600571]
A06AD11 [21600571]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
0
14
114
1087
0
6
114
1095
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
9
113
1088
—
Tooth plaque
K03.66 [2000502691]
K03.66 [2000502691]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
5
114
1096
—
—
—
—
0
5
113
1092
—
Monitoring of normal pregnancy
SPAT1196 [2001700297]
SPAT1196 [2001700297]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
oxcarbazepine; oral
N03AF02 [21604418]
N03AF02 [21604418]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.83%
—
—
—
—
—
0
5
113
1092
0
9
112
1072
Other administrative function
SPAT1281 [2001700382]
SPAT1281 [2001700382]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Rheumatology
66 [38004491]
66 [38004491]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.45%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
0
16
114
1085
0
9
114
1092
—
—
—
—
—
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
C03EA01 [21601543]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.36%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
0
15
114
1086
0
6
114
1095
—
—
—
0
7
113
1090
—
enalapril; oral, parenteral
C09AA02 [21601786]
C09AA02 [21601786]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:2.00%
cases:0.00%
controls:0.54%
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:2.01%
cases:0.00%
controls:3.15%
—
0
22
114
1079
0
6
114
1095
—
0
9
114
1092
0
22
113
1075
0
34
112
1047
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
6357-8 [3024950]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
fluoxetine; oral
N06AB03 [21604711]
N06AB03 [21604711]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
0
6
114
1095
—
—
—
0
9
113
1088
—
citalopram; oral, parenteral
N06AB04 [21604712]
N06AB04 [21604712]
—
—
-1.0e+50
—
—
—
6.0e-01
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:4.46%
controls:2.50%
—
—
0
5
114
1096
—
—
—
5
27
107
1054
Medical Oncology
90 [38004507]
90 [38004507]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
0
9
114
1092
0
5
114
1096
—
—
—
0
8
113
1089
—
Simple partial seizures with secondary generalization
G40.12 [2000502137]
G40.12 [2000502137]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Pain localized to upper abdomen
R10.1 [45568111]
R10.1 [45568111]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
114
1093
—
—
—
—
—
—
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
R87.6 [45558487]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
0
12
112
1069
Teeth/gum symptom/complaint
D19 [2002000318]
D19 [2002000318]
—
-1.0e+50
—
—
—
-1.0e+50
9.6e-02
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:4.46%
controls:4.07%
—
0
8
114
1093
—
—
—
0
8
113
1089
5
44
107
1037
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
I25.9 [45552784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
—
—
—
—
—
—
4.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:4.26%
—
—
—
—
—
—
7
46
105
1035
norethisterone and ethinylestradiol
G03AA05 [21602478]
G03AA05 [21602478]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
0
8
114
1093
—
—
—
—
—
loperamide; oral
A07DA03 [21600646]
A07DA03 [21600646]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Type 1 diabetes mellitus, With ketoacidosis
E10.1 [45542735]
E10.1 [45542735]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
13
112
1068
hyaluronic acid
S01KA01 [21605114]
S01KA01 [21605114]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Insertion of intrauterine device
TLC00 [2001306647]
TLC00 [2001306647]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Psychologist
Z2445 [2001311558]
Z2445 [2001311558]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
19232-8 [3007628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
11
112
1070
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
11572-5 [3021614]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
114
1092
—
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:2.22%
—
0
5
114
1096
—
—
—
0
7
113
1090
0
24
112
1057
Throat symptom/complaint
R21 [2002000891]
R21 [2002000891]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
Deviated nasal septum
J34.2 [45562448]
J34.2 [45562448]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Flank/axilla symptom/complaint
L05 [2002000630]
L05 [2002000630]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
azithromycin; oral, parenteral
J01FA10 [21602978]
J01FA10 [21602978]
3.0e-01
6.5e-01
—
—
—
4.5e-01
1.4e-01
cases:17.54%
controls:13.62%
cases:5.26%
controls:2.82%
—
—
—
—
—
—
cases:5.31%
controls:3.46%
cases:12.50%
controls:11.01%
20
150
94
951
6
31
108
1070
—
—
—
6
38
107
1059
14
119
98
962
Other intraoperative electrophysiological investigation in arhythmia or disturbance of impulse propagation
XFP96 [2001303143]
XFP96 [2001303143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
SPAT1250 [2001700351]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
0
8
113
1089
—
chloramphenicol
G01AA05 [21602367]
G01AA05 [21602367]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
10
112
1071
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
8.8e-01
1.0e+00
—
1.0e+50
—
1.7e+00
5.8e-01
cases:6.14%
controls:2.63%
cases:4.39%
controls:1.63%
—
—
cases:5.26%
controls:0.00%
—
—
cases:5.31%
controls:1.00%
cases:6.25%
controls:3.61%
7
29
107
1072
5
18
109
1083
—
6
0
108
1101
—
6
11
107
1086
7
39
105
1042
chlorhexidine
S02AA09 [21605155]
S02AA09 [21605155]
—
—
—
—
—
-1.0e+50
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:4.46%
controls:1.67%
—
—
—
—
—
0
6
113
1091
5
18
107
1063
Laparoscopic appendectomy
JEA01 [2001304803]
JEA01 [2001304803]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
9
112
1072
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.94%
—
0
10
114
1091
—
—
—
—
0
21
112
1060
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
30934-4 [3011960]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
—
—
—
—
-1.0e+50
—
3.4e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
cases:8.04%
controls:5.83%
—
—
—
—
0
5
114
1096
—
9
63
103
1018
Vaccination
SPAT1325 [2001700426]
SPAT1325 [2001700426]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
9
113
1088
—
Dizziness and giddiness
R42 [45568132]
R42 [45568132]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
0
10
114
1091
—
—
—
—
—
0
10
112
1071
Pulmonary Disease
29 [38004472]
29 [38004472]
—
1.1e+00
—
—
—
—
5.9e-01
—
—
cases:4.39%
controls:1.45%
—
—
—
—
—
—
—
—
cases:7.14%
controls:4.07%
—
5
16
109
1085
—
—
—
—
8
44
104
1037
Social worker
Z2446 [2001311559]
Z2446 [2001311559]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
Inpatient Visit
IP [9201]
IP [9201]
1.8e-03
—
-1.0e+50
1.0e+50
—
7.5e-01
5.5e-01
cases:12.28%
controls:12.26%
—
—
cases:0.00%
controls:0.73%
cases:8.77%
controls:0.00%
—
—
cases:6.19%
controls:3.01%
cases:8.04%
controls:4.81%
14
135
100
966
—
0
8
114
1093
10
0
104
1101
—
7
33
106
1064
9
52
103
1029
Other investigative procedure of eye
XCW99 [2001301491]
XCW99 [2001301491]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
0
5
114
1096
—
—
—
0
6
113
1091
—
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
113
1092
—
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
2731-8 [3000067]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
Celiac disease serology panel - Serum
94494-2 [36660697]
94494-2 [36660697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
10
112
1071
One-surface restoration
SFA10 [2001310358]
SFA10 [2001310358]
5.7e-01
1.5e+00
—
—
—
—
5.2e-01
cases:7.02%
controls:4.09%
cases:4.39%
controls:1.00%
—
—
—
—
—
—
—
—
cases:15.18%
controls:9.62%
8
45
106
1056
5
11
109
1090
—
—
—
—
17
104
95
977
desogestrel
G03AC09 [21602505]
G03AC09 [21602505]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
10
112
1071
Postmenopausal bleeding
N95.0 [45567872]
N95.0 [45567872]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
Shortness of breath/dyspnoea
R02 [2002000883]
R02 [2002000883]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
Plantar fascial fibromatosis
M72.2 [45553265]
M72.2 [45553265]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
metronidazole; oral, rectal
P01AB01 [21604857]
P01AB01 [21604857]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
—
0
18
114
1083
—
—
—
—
—
Internal Medicine
11 [38004456]
11 [38004456]
-2.4e-01
-1.5e-01
-1.0e+50
—
-1.0e+50
-8.3e-02
-4.7e-01
cases:10.53%
controls:12.99%
cases:5.26%
controls:6.09%
cases:0.00%
controls:0.64%
—
—
cases:0.00%
controls:1.18%
cases:5.31%
controls:5.74%
cases:9.82%
controls:14.80%
12
143
102
958
6
67
108
1034
0
7
114
1094
—
0
13
114
1088
6
63
107
1034
11
160
101
921
Acute bronchitis
J20 [45581849]
J20 [45581849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
47210-0 [3048773]
—
—
—
—
—
—
-3.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.93%
controls:11.84%
—
—
—
—
—
—
10
128
102
953
Outcome of delivery
Z37 [45581024]
Z37 [45581024]
1.5e-01
-1.0e+50
—
—
—
—
7.3e-02
cases:7.02%
controls:6.09%
cases:0.00%
controls:2.00%
—
—
—
—
—
—
—
—
cases:4.46%
controls:4.16%
8
67
106
1034
0
22
114
1079
—
—
—
—
5
45
107
1036
Migraine without aura [common migraine]
G43.0 [45600784]
G43.0 [45600784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
—
Extensive health check-up on first grade
SPAT1384 [2001700484]
SPAT1384 [2001700484]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
terbutaline; inhalant
R03AC03 [21603257]
R03AC03 [21603257]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
betamethasone
C05AA05 [21601610]
C05AA05 [21601610]
3.4e-01
—
—
—
—
—
-8.9e-02
cases:5.26%
controls:3.81%
—
—
—
—
—
—
—
—
—
—
cases:5.36%
controls:5.83%
6
42
108
1059
—
—
—
—
—
6
63
106
1018
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
6
113
1091
—
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
CJE20 [2001301342]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
Atherosclerotic heart disease
I25.1 [45596196]
I25.1 [45596196]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
9
113
1088
—
Ganglion
M67.4 [45582222]
M67.4 [45582222]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
9
112
1072
fluticasone; nasal
R01AD08 [21605050]
R01AD08 [21605050]
2.7e-01
—
—
—
—
5.3e-01
4.4e-01
cases:7.02%
controls:5.45%
—
—
—
—
—
—
—
—
cases:5.31%
controls:3.19%
cases:11.61%
controls:7.77%
8
60
106
1041
—
—
—
—
6
35
107
1062
13
84
99
997
Genetic counselling
Z31.5 [45590715]
Z31.5 [45590715]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
0
7
114
1094
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
L15 [2002000639]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
114
1093
—
—
—
—
—
—
Endomysium IgA Ab [Titer] in Serum
10863-9 [3020961]
10863-9 [3020961]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
glucosamine; oral
M01AX05 [21604002]
M01AX05 [21604002]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
0
8
113
1089
—
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
0
9
114
1092
—
—
—
0
10
113
1087
—
Upper respiratory infection acute
R74 [2002000942]
R74 [2002000942]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
0
10
114
1091
—
—
—
0
9
113
1088
—
Gas panel - Capillary blood
24337-8 [3022313]
24337-8 [3022313]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Uroflowmetry
44856007 [4261340]
44856007 [4261340]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
naproxen; oral, rectal
M01AE02 [21603968]
M01AE02 [21603968]
1.5e-01
—
—
—
-1.0e+50
7.9e-01
-1.7e-01
cases:12.28%
controls:10.72%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:6.19%
controls:2.92%
cases:8.93%
controls:10.45%
14
118
100
983
—
—
—
0
5
114
1096
7
32
106
1065
10
113
102
968
sildenafil; oral
G04BE03 [21602648]
G04BE03 [21602648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
114
1095
—
—
—
—
—
—
Other general examinations
Z00.8 [45581001]
Z00.8 [45581001]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
SFC01 [2001310369]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
0
6
114
1095
—
—
—
0
9
113
1088
—
sitagliptin; oral
A10BH01 [21600784]
A10BH01 [21600784]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
113
1092
—
Acute lymphoblastic leukaemia [ALL]
C91.0 [45537873]
C91.0 [45537873]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
7
114
1094
0
5
114
1096
—
—
—
—
0
6
112
1075
Rectocele
N81.6 [45543893]
N81.6 [45543893]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
Urine culture
117010004 [4024509]
117010004 [4024509]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
Specialty-specific consultation based on referral by dentist or doctor
WZC05 [2001310886]
WZC05 [2001310886]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.48%
—
—
—
—
—
—
7
16
105
1065
Cardiology
6 [38004451]
6 [38004451]
—
—
—
—
—
1.4e+00
8.4e-01
—
—
—
—
—
—
—
—
—
—
cases:4.42%
controls:1.09%
cases:8.93%
controls:4.07%
—
—
—
—
—
5
12
108
1085
10
44
102
1037
fluticasone; inhalant
R03BA05 [21603288]
R03BA05 [21603288]
9.7e-02
—
-1.0e+50
—
—
—
8.8e-01
cases:4.39%
controls:4.00%
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:6.25%
controls:2.68%
5
44
109
1057
—
0
5
114
1096
—
—
—
7
29
105
1052
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
N04AB02 [21604458]
3.9e-01
—
—
—
—
-1.0e+50
—
cases:4.39%
controls:3.00%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
5
33
109
1068
—
—
—
—
0
16
113
1081
—
Skin texture symptom/complaint
S21 [2002000986]
S21 [2002000986]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
11
112
1070
rofecoxib; oral
M01AH02 [21603993]
M01AH02 [21603993]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
0
9
114
1092
—
—
—
0
9
113
1088
—
Low back pain
M54.5 [45553207]
M54.5 [45553207]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
0
12
114
1089
0
7
114
1094
—
—
—
0
10
113
1087
—
tamsulosin; oral
G04CA02 [21602669]
G04CA02 [21602669]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:1.57%
0
5
114
1096
0
6
114
1095
—
—
—
0
7
113
1090
0
17
112
1064
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
112
1074
cough suppressants and expectorants
R05FB02 [21603442]
R05FB02 [21603442]
8.7e-01
—
—
—
—
-1.0e+50
—
cases:5.26%
controls:2.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
6
25
108
1076
—
—
—
—
0
5
113
1092
—
Primary gonarthrosis, bilateral
M17.0 [45562648]
M17.0 [45562648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
114
1096
—
—
—
—
—
—
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
tinzaparin; parenteral
B01AB10 [21600981]
B01AB10 [21600981]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Neurosurgery
14 [38004459]
14 [38004459]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.00%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
0
22
114
1079
—
—
—
—
0
10
113
1087
—
tacrolimus
D11AH01 [21602338]
D11AH01 [21602338]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
112
1075
diltiazem; oral
C08DB01 [21601771]
C08DB01 [21601771]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
5
114
1096
—
—
—
—
—
0
6
112
1075
Intraoral radiographic dental examination
EB1AA [2001301903]
EB1AA [2001301903]
7.5e-01
—
—
—
—
1.1e+00
3.6e-01
cases:7.89%
controls:3.91%
—
—
—
—
—
—
—
—
cases:4.42%
controls:1.55%
cases:9.82%
controls:7.03%
9
43
105
1058
—
—
—
—
5
17
108
1080
11
76
101
1005
Mild cervical dysplasia
N87.0 [45567868]
N87.0 [45567868]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
5
112
1076
Telephone prescription or other care instructions
WZB00 [2001310884]
WZB00 [2001310884]
—
—
—
—
—
—
4.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:4.07%
—
—
—
—
—
—
7
44
105
1037
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
—
0
16
113
1081
—
Simple examination of mouth
SAA01 [2001310274]
SAA01 [2001310274]
2.9e-01
5.5e-01
—
—
—
5.6e-01
3.1e-01
cases:8.77%
controls:6.72%
cases:6.14%
controls:3.63%
—
—
—
—
—
—
cases:6.19%
controls:3.65%
cases:18.75%
controls:14.52%
10
74
104
1027
7
40
107
1061
—
—
—
7
40
106
1057
21
157
91
924
Eye discharge
F03 [2002000401]
F03 [2002000401]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
5
114
1096
—
—
—
—
—
0
6
112
1075
chlorphenamine, combinations
R06AB54 [21603468]
R06AB54 [21603468]
7.9e-01
—
—
—
—
-1.0e+50
—
cases:5.26%
controls:2.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
6
27
108
1074
—
—
—
—
0
6
113
1091
—
Acute tonsillitis, unspecified
J03.9 [45576942]
J03.9 [45576942]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
114
1091
—
—
—
—
—
—
Other specified pulpit
K04.08 [2000502703]
K04.08 [2000502703]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
5
114
1096
—
—
—
—
—
0
6
112
1075
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
13
49
2.71
2.65
1.4
1.3
—
—
—
0
0
14
58
2.46
2.39
1.1
1.4
—
—
—
0
0
50
328
1.60
2.33
8.0
9.8
104.90
104.60
mmol/l
0.21
50
328
8
28
2.89
1.87
1.1
1.1
1514.25
1590.14
miu/ml
—
8
28
36
232
1.61
1.83
9.0
13.4
1.84
0.60
mmol/l
1.33
29
189
8
31
2.61
1.66
1.1
1.2
—
—
—
0
0
111
1340
0.76
1.64
1.8
1.8
1.32
1.35
mmol/l
0.13
102
1207
7
26
2.72
1.58
1.1
2.6
—
0.79
—
0
10
7
27
2.62
1.52
1.0
3.9
—
—
—
0
0
14
72
1.98
1.50
4.2
3.0
2.50
2.90
index
—
6
40
18
107
1.71
1.28
6.6
4.7
55.71
50.58
%
0.43
18
107
6
25
2.42
1.25
1.0
1.1
—
—
—
0
0
23
148
1.59
1.23
12.2
14.6
1.46
1.37
%
0.14
23
148
6
26
2.33
1.19
3.8
1.6
10.50
10.81
mmol/l
—
6
26
6
26
2.33
1.19
1.0
1.2
—
—
—
0
0
13
219
0.58
1.13
1.6
1.7
0.53
0.29
mg/l
—
6
96
50
641
0.75
1.12
1.3
1.3
16.54
8.35
u/ml
0.33
23
258
22
144
1.56
1.11
12.4
15.0
0.74
0.67
%
0.38
22
144
22
146
1.54
1.05
12.6
14.8
96.03
94.17
%
1.93
22
146
135
1183
1.21
1.03
5.3
5.6
36.93
37.62
g/l
0.75
130
1131
7
35
2.02
1.00
1.1
1.4
—
—
—
0
0
25
176
1.45
0.93
1.8
1.8
—
—
—
0
0
84
985
0.81
0.92
2.1
2.2
—
—
—
0
0
92
1065
0.82
0.88
2.3
2.3
—
—
—
0
0
314
3269
0.82
0.87
3.8
3.9
1.46
1.45
mmol/l
0.25
304
3146
23
319
0.70
0.86
1.6
1.6
66.59
62.03
ug/l
0.21
17
268
14
88
1.61
0.85
1.3
1.3
—
—
—
0
0
8
45
1.79
0.84
1.0
1.0
—
—
—
0
0
45
561
0.78
0.84
1.8
2.0
—
—
—
0
0
316
3284
0.82
0.83
3.9
4.0
4.79
4.70
mmol/l
0.97
305
3166
11
65
1.71
0.83
1.9
1.5
—
—
—
0
0
193
1774
1.17
0.82
5.1
5.7
6.18
6.32
mmol/l
0.49
173
1612
6
32
1.89
0.82
2.0
1.6
0.57
0.48
e9/l
—
6
32
94
815
1.20
0.80
3.0
3.2
0.66
0.21
e6/l
0.74
74
570
0
24
0.00
0.79
0.0
1.0
—
93.53
—
0
17
0
24
0.00
0.79
0.0
3.4
—
639.29
—
0
24
0
24
0.00
0.79
0.0
1.0
—
101.53
—
0
17
6
33
1.83
0.79
1.2
1.4
—
—
—
0
0
6
33
1.83
0.79
1.2
1.4
—
—
—
0
0
6
33
1.83
0.79
1.2
1.4
—
—
—
0
0
26
191
1.39
0.79
2.8
5.5
1.04
0.90
mmol/l
0.09
17
136
13
197
0.65
0.77
1.2
1.5
—
—
—
0
0
13
83
1.59
0.76
1.4
1.5
439.17
289.37
ug/g
—
6
42
318
3295
0.83
0.75
4.1
4.2
2.93
2.84
mmol/l
1.21
306
3166
10
60
1.68
0.72
2.3
5.5
366.30
371.70
umol/l
—
10
53
28
212
1.34
0.72
1.1
1.1
1.52
1.52
g/l
0.02
28
212
209
1952
1.15
0.68
3.4
3.3
69.45
79.46
ug/l
0.81
199
1874
5
94
0.53
0.67
1.2
1.8
—
—
—
0
0
28
215
1.32
0.67
1.1
1.1
0.98
0.89
g/l
1.06
28
215
340
3295
1.21
0.67
12.3
12.1
139.52
139.58
mmol/l
0.16
330
3226
368
3597
1.27
0.65
13.5
13.0
71.33
69.56
umol/l
0.32
363
3556
146
1336
1.15
0.63
8.3
8.4
1.21
1.22
mmol/l
0.34
133
1173
51
427
1.22
0.63
2.9
2.5
2.42
2.42
g/l
0.02
46
395
61
709
0.84
0.62
1.3
1.3
20.05
22.68
iu/ml
0.14
18
206
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.3
—
—
—
0
0
0
22
0.00
0.59
0.0
1.6
—
—
—
0
0
6
35
1.72
0.58
1.2
1.4
—
—
—
0
0
6
35
1.72
0.58
1.2
1.4
—
—
—
0
0
19
141
1.36
0.57
1.1
1.1
0.80
9.22
eliau/ml
—
5
26
12
172
0.69
0.57
1.2
1.2
15.05
3.63
u/ml
—
6
98
129
1179
1.14
0.57
7.7
8.1
1.20
1.22
mmol/l
0.93
120
1102
5
86
0.58
0.57
1.2
1.5
—
—
—
0
0
6
38
1.59
0.54
1.2
1.3
—
—
—
0
0
18
134
1.36
0.54
1.5
1.3
—
—
—
0
0
61
699
0.85
0.53
2.9
2.9
326.59
322.00
umol/l
0.15
56
658
23
292
0.77
0.53
1.7
1.5
—
—
—
0
0
46
537
0.84
0.50
1.6
1.6
1139.22
973.05
mu/l
0.36
36
456
151
1404
1.12
0.50
4.0
3.1
0.00
0.03
estimate
1.22
33
317
7
108
0.64
0.49
1.1
1.2
—
—
—
0
0
7
108
0.64
0.49
1.1
1.2
—
—
—
0
0
7
109
0.64
0.49
1.7
2.1
—
—
—
0
0
7
45
1.57
0.49
1.0
1.5
—
—
—
0
0
391
3866
1.42
0.48
18.8
18.1
270.80
261.62
e9/l
2.08
384
3817
338
3298
1.16
0.47
12.6
12.1
3.93
3.92
mmol/l
0.50
326
3217
56
489
1.17
0.46
2.7
3.2
332.03
584.83
ng/l
0.27
31
269
24
297
0.80
0.46
1.6
1.5
1.00
1.19
ratio
0.59
12
188
24
297
0.80
0.46
1.6
1.5
1.20
1.19
ratio
0.02
12
188
24
297
0.80
0.46
1.6
1.5
0.90
0.98
ratio
0.68
12
188
51
585
0.85
0.46
2.3
1.8
1.40
1.36
%
0.13
45
540
125
1157
1.12
0.44
1.7
1.9
102.64
96.92
pmol/l
0.73
67
632
13
95
1.38
0.44
1.3
1.9
—
—
—
0
0
391
3869
1.39
0.43
18.7
18.1
4.59
4.59
e12/l
0.11
384
3815
15
195
0.76
0.42
1.4
1.8
2.59
3.33
mg/l
—
9
131
60
674
0.87
0.42
2.0
2.2
—
—
—
0
0
192
1823
1.10
0.42
4.1
3.3
0.00
0.00
estimate
0.50
36
372
195
1853
1.10
0.42
4.1
3.4
0.00
0.01
estimate
0.50
37
351
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
2.9
—
123.50
—
0
16
28
232
1.22
0.41
12.3
12.3
1.30
1.35
mmol/l
0.10
28
226
21
168
1.26
0.41
1.4
1.4
—
—
—
0
0
194
1845
1.10
0.41
4.1
3.4
0.00
7.90
estimate
0.80
39
369
7
101
0.69
0.40
1.6
1.9
—
—
—
0
0
64
712
0.88
0.39
1.8
1.5
18.08
20.49
nmol/l
0.89
57
639
38
327
1.18
0.39
1.6
1.5
1002.77
1190.27
nmol/l
0.76
30
261
25
300
0.82
0.38
2.6
3.3
31.70
32.30
%
0.09
20
220
17
134
1.28
0.37
7.7
6.8
0.63
0.62
%
0.05
17
134
92
849
1.11
0.35
1.6
1.6
—
—
—
0
0
42
477
0.87
0.35
2.3
2.3
2.43
2.41
mmol/l
0.49
37
423
353
3471
1.14
0.34
12.5
12.0
22.02
20.40
mg/l
0.41
295
2724
26
221
1.19
0.31
12.5
13.0
25.51
24.85
mmol/l
0.61
26
221
253
2605
0.92
0.31
3.4
3.4
32.46
35.59
u/l
0.85
245
2529
318
3114
1.10
0.31
10.1
9.9
95.20
95.84
ml/min/173m2
0.21
278
2769
12
153
0.78
0.31
1.8
2.1
37.92
40.34
u/l
0.29
12
142
16
129
1.25
0.30
2.4
4.9
3.08
3.28
g/l
0.30
16
124
315
3212
0.91
0.30
5.1
5.2
1.80
1.74
mu/l
0.48
305
3079
28
241
1.17
0.30
2.3
2.7
—
—
—
0
0
32
364
0.87
0.28
1.5
1.4
—
—
—
0
0
8
62
1.30
0.28
1.5
1.6
8.61
7.38
mmol/l
—
8
62
9
117
0.76
0.28
1.0
1.3
—
2.66
—
0
10
302
3079
0.92
0.26
3.3
3.4
1.26
1.21
mmol/l
0.53
289
2939
93
989
0.92
0.26
2.6
3.1
2.37
2.35
mmol/l
0.56
81
925
9
74
1.22
0.25
5.4
7.3
—
3425.00
—
0
8
75
804
0.92
0.25
2.2
2.0
140.74
255.87
u/l
0.77
70
771
237
2433
0.94
0.24
4.3
4.0
9.72
8.33
mm/h
1.02
229
2309
6
85
0.70
0.24
1.0
1.3
—
1.28
—
0
5
86
808
1.08
0.24
2.9
2.3
2.60
2.57
mg/l
0.05
78
705
117
1228
0.93
0.23
3.2
3.6
26.86
29.35
u/l
0.79
112
1177
33
295
1.13
0.23
1.7
1.8
—
—
—
0
0
16
189
0.84
0.23
1.6
1.5
46.98
53.28
ug/l
0.24
16
189
7
92
0.76
0.22
1.0
1.9
3.30
3.48
mmol/l
—
7
87
231
2369
0.94
0.22
7.4
7.4
87.59
77.53
u/l
0.45
221
2251
10
124
0.80
0.22
1.3
1.2
—
2.57
—
0
6
206
2001
1.06
0.21
9.3
9.9
4.26
3.89
e9/l
1.48
187
1751
0
11
0.00
0.21
0.0
1.2
—
7.62
—
0
11
0
10
0.00
0.21
0.0
1.2
—
22.83
—
0
10
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
8
104
0.76
0.21
1.4
1.2
—
60.77
—
0
10
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
3.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
3.4
—
—
—
0
0
6
50
1.20
0.20
1.3
1.4
27.73
35.20
nmol/l
—
6
40
23
203
1.14
0.19
1.6
2.0
—
—
—
0
0
6
51
1.18
0.19
6.0
4.3
7.25
6.33
pmol/l
—
6
51
286
2909
0.94
0.19
4.3
4.6
37.25
37.20
mmol/mol
0.03
273
2804
96
914
1.07
0.19
3.2
2.8
30.74
47.29
ng/l
0.34
51
410
13
109
1.20
0.19
1.5
1.7
280.62
219.01
pmol/l
1.34
13
104
33
300
1.11
0.18
1.7
1.7
—
—
—
0
0
7
60
1.17
0.18
1.9
2.3
—
—
—
0
0
363
3597
1.09
0.17
9.9
9.8
27.21
27.35
u/l
0.04
354
3535
301
3052
0.95
0.16
3.6
3.7
5.59
5.64
mmol/l
0.27
282
2884
34
370
0.91
0.16
1.1
1.3
53.19
163.49
u/ml
3.21
13
156
19
168
1.14
0.16
1.6
1.7
—
—
—
0
0
6
77
0.78
0.15
1.3
1.5
—
—
—
0
0
6
79
0.76
0.15
15.7
2.5
0.62
0.91
nmol/l
—
6
69
16
182
0.87
0.15
1.3
1.6
—
—
—
0
0
18
159
1.14
0.15
1.3
1.2
—
—
—
0
0
114
1100
1.05
0.15
3.7
2.7
0.03
0.02
estimate
0.10
32
307
29
266
1.10
0.14
4.0
5.2
—
—
—
0
0
28
257
1.10
0.13
1.3
1.4
—
—
—
0
0
87
837
1.05
0.13
3.7
3.3
1.02
1.02
kg/l
0.25
51
536
309
3056
1.05
0.12
4.0
3.9
—
—
—
0
0
162
1583
1.04
0.12
2.8
2.8
—
—
estimate
—
0
0
11
126
0.87
0.11
2.5
1.5
—
—
—
0
0
24
259
0.92
0.10
1.8
4.0
4.67
4.84
pmol/l
0.35
24
232
109
1120
0.96
0.10
1.2
1.4
0.72
2.10
u/ml
1.77
29
297
10
114
0.87
0.09
2.3
1.6
—
—
—
0
0
20
217
0.92
0.09
1.8
1.8
—
—
—
0
0
50
478
1.05
0.09
3.4
2.9
4.10
3.57
e6/l
0.15
24
216
23
247
0.93
0.09
2.2
2.0
0.73
0.68
ug/l
—
10
102
41
430
0.95
0.08
1.8
1.9
—
—
—
0
0
6
71
0.84
0.07
1.3
1.1
—
—
—
0
0
7
85
0.82
0.07
1.1
1.7
—
—
—
0
0
7
85
0.82
0.07
1.1
1.4
14.40
17.15
u/l
—
7
70
11
122
0.90
0.07
1.2
1.4
—
—
—
0
0
125
1227
1.03
0.07
1.8
1.8
—
—
—
0
0
18
193
0.93
0.06
6.3
2.1
66.08
31.83
u/ml
0.38
18
183
30
314
0.95
0.06
2.7
3.0
17.97
22.69
%
—
9
91
23
243
0.94
0.06
1.2
1.3
—
17.30
—
0
17
47
456
1.03
0.05
1.6
1.6
3.61
3.44
mmol/l
0.43
29
316
27
258
1.05
0.05
1.4
1.4
179.91
271.28
miu/ml
0.97
15
139
51
497
1.03
0.04
4.0
3.7
714.98
651.64
ng/l
0.11
42
391
277
2786
0.98
0.04
4.3
4.5
14.44
14.43
pmol/l
0.02
265
2627
78
769
1.02
0.02
1.9
2.2
0.69
1.03
mg/l
1.17
61
576
51
502
1.02
0.01
1.9
1.6
442.78
48344799.05
pmol/l
1.07
45
453
96
952
1.01
0.01
4.1
3.4
0.05
0.01
estimate
0.39
37
360
11
104
1.06
0.01
1.6
1.4
62.82
89.86
pmol/l
0.31
11
98
13
136
0.95
0.00
2.0
2.0
7.37
6.08
ug/l
0.17
13
124
13
136
0.95
0.00
8.2
10.6
1.17
1.21
mg/l
0.11
13
129
29
284
1.02
0.00
1.0
1.0
—
—
—
0
0
51
504
1.01
0.00
3.4
2.8
0.82
0.72
e6/l
0.13
25
242
80
806
0.99
0.00
2.1
2.2
—
—
—
0
0
154
1546
0.99
0.00
4.6
6.6
12.25
10.78
umol/l
0.37
144
1482
69
692
1.00
0.00
3.8
4.4
5.52
8.96
mg/mmol
0.67
45
469
17
171
0.99
0.00
2.6
4.7
184.15
9.37
ug/l
—
10
130
21
209
1.01
0.00
1.2
1.4
—
—
—
0
0
148
1478
1.00
0.00
3.1
2.8
71.80
72.56
nmol/l
0.13
141
1397
25
251
1.00
0.00
1.8
1.6
—
—
—
0
0
14
137
1.02
0.00
1.2
2.2
2.93
4.26
iu/l
—
6
57
13
135
0.96
0.00
2.0
1.5
95.00
219.82
u/ml
—
8
79
58
583
0.99
0.00
1.9
1.8
3.67
3.42
ratio
0.61
42
438
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
1.20
—
0
9
9
98
0.92
-0.00
1.0
2.0
487.44
387.34
mg/l
—
9
92
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
69
1.01
-0.00
1.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
2.69
—
0
7
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
76
0.92
-0.00
1.1
1.5
—
—
—
0
0
5
55
0.91
-0.00
1.0
3.7
61.06
5.82
u/ml
—
5
55
6
63
0.95
-0.00
1.0
1.3
—
—
—
0
0
39
390
1.00
-0.00
2.2
2.3
1184.82
6497.07
u/l
2.27
18
165
Mortality – FinRegistry
↥Association
Association between endpoint Q17_CLEFT_PALATE and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| Q17_CLEFT_PALATE | 1.685 [1.24, 2.3] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.008 |
During the follow-up period (1.1.1998 — 31.12.2019), 51 out of 1196 males with Q17_CLEFT_PALATE died.
Mortality risk
Mortality risk for people of age
years, who have Q17_CLEFT_PALATE.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.31% |
| 5 | No data | 2.108% |
| 10 | No data | 4.96% |
| 15 | No data | 9.258% |
| 20 | No data | 15.23% |
Relationships between endpoints
↥Index endpoint: Q17_CLEFT_PALATE – Cleft palate
GWS hits: 5
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data